Skip to Main Content

Paper Details

Unleashing T cell anti-tumor immunity: new potential for 5-Nonloxytryptamine as an agent mediating MHC-I upregulation in tumors.
Mol Cancer
0
2023
5-NL, 5-Nonloxytryptamine, 5-Nonyloxytryptamine, CD8, CD8 T cells, CREB, Cas9, LCMV, LCMV gp33 CTL epitope, MHC-I, PD-L1, RNA, T cell, T cells, anti-PD-1, anti-PD1, cAMP, cAMP Response Element-Binding Protein, lymphocytic, lymphocytic choriomeningitis virus, lymphocytic choriomeningitis virus (LCMV)-primed splenic T cells, melanoma, melanoma B16, mice, patients, serotonin, tumor, tumor cells, tumors
Author NameAffiliation
Daniel PicardHematology and Clinical Immunology, Heinrich-Heine-University
Daniel PicardGerman Cancer Research Center (DKFZ)
Daniel Picard
Daniel PicardHeinrich-Heine University
Marc RemkeHematology and Clinical Immunology, Heinrich-Heine-University
Marc RemkeGerman Cancer Research Center (DKFZ)
Marc Remke
Marc RemkeHeinrich-Heine University
Arndt BorkhardtHematology and Clinical Immunology, Heinrich-Heine-University
Arndt BorkhardtHematology and Clinical Immunology, Heinrich-Heine-University
Aleksandra A PandyraHematology and Clinical Immunology, Heinrich-Heine-University
Aleksandra A PandyraUniversity Hospital Bonn
Aleksandra A PandyraGerman Center for Infection Research (DZIF)
  • 1 - 13

Datasets

Release 1.2